(Q39263953)

10 September 2017

HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors (English)

1 reference

10 September 2017

S Gusenbauer

1

1 reference

10 September 2017

P Vlaicu

series ordinal

2

1 reference

10 September 2017

A Ullrich

series ordinal

3

1 reference

10 September 2017

language of work or name

English

0 references

publication date

8 October 2012

1 reference

10 September 2017

1 reference

10 September 2017

32

1 reference

10 September 2017

3846-3856

1 reference

10 September 2017

33

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2012.396

10 September 2017

0 references

cites work

Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Pharmacological background of EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

STAT-mediated EGFR signaling in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Common and distinct elements in cellular signaling via EGF and FGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

EGFR signaling and drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Why Iressa failed: toward novel use of kinase inhibitors (outlook).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Failing survival advantage in crucial trial, future of Iressa is in jeopardy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Targeting epidermal growth factor receptor: central signaling kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Met, metastasis, motility and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Tumor stroma and regulation of cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Mechanism of biological synergy between cellular Src and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Proteomics strategy for quantitative protein interaction profiling in cell extracts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

Epidermal growth factor receptor dependence in human tumors: more than just expression?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.396

31 March 2020

Identifiers

DOI

10.1038/ONC.2012.396

1 reference

10 September 2017

1 reference